<DOC>
	<DOCNO>NCT02268032</DOCNO>
	<brief_summary>Evaluate effect continuous administration DHEA androgenic agent ovarian reserve marker woman diminish ovarian reserve ( ROD ) , antral follicle count AMH concentration .</brief_summary>
	<brief_title>Assess Effect Dehydroepiandrosterone ( DHEA ) Other Androgenic Agents Over Markers Ovarian Reserve</brief_title>
	<detailed_description>Healthy woman protect pregnancy surgical sterilization , contraindication use androgen therapy , attend clinic IDIMI invite participate . Project Objetives : The general objective evaluate pharmacokinetic parameter three vaginal ring local extend release , contain dehydroepiandrosterone ( DHEA ) , testosterone association hormone , compare oral administration DHEA testosterone transdermal woman Secondary objective assess effect hormonal profile , tolerability incidence adverse event . - DHEA and/or , testosterone level - Estradiol , FSH , SHBG , androstenediona , cortisol matinal , IGF1.levels - Tolerability safety assessment use vaginal ring . - The incidence adverse event</detailed_description>
	<mesh_term>Dehydroepiandrosterone</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>1 . Women 38 45 year age use hormonal contraceptive method least past two month , surgically sterilize , contraindication androgenic therapy . 2 . Women preserve menstrual cycle . 3 . Women smoke less 5 cigarette daily . 4 . AMH 0.51.1 ng/mL 5 . Total AFC 57 1 . Women receive medication interact DHEA metabolism ( Anastrozole , exemestane , Fulvestrant , Insulin , Letrozole , Tamoxifen , Triazolam ) . 2 . Women diabetes mellitus 3 . Women untreated decompensated endocrine disorder 4 . Women prior history ovarian surgery oophorectomy</criteria>
	<gender>Female</gender>
	<minimum_age>38 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>hormone replacement therapy</keyword>
</DOC>